Profile data is unavailable for this security.
About the company
BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The Company is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. It also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.
- Revenue in USD (TTM)13.07bn
- Net income in USD6.68bn
- LocationBioNTech SEAn der Goldgrube 12MAINZ 55131GermanyDEU
- Phone+49 49 613190840
- Fax+49 61 319084390
Mergers & acquisitions
|Acquired company||Deal status||Date||Date /|
|22UA:GER since |
|Instadeep Ltd||Announced||10 Jan 2023||10 Jan 2023Announced||-31.32%||684.69m|
|Ryvu Therapeutics SA||Announced||30 Nov 2022||30 Nov 2022Announced||-38.66%||--|
|Novartis Singapore Pharmaceutical Manufacturing Pte Ltd-Gpm Manufacturing Site||Announced||14 Nov 2022||14 Nov 2022Announced||-33.74%||--|